Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(eosinophil differentiation factor)
7,260 results
  • [Levels of airway inflammatory mediators in peripheral blood in infants and young children with wheezing]. [Journal Article]
    Zhongguo Dang Dai Er Ke Za Zhi 2019; 21(9):861-867Yu XH, He M, … Kuang J
  • CONCLUSIONS: Th1/Th2 imbalance with a predominance of Th2 is observed in infants and young children with wheezing. IL-4, IL-5, IL-13, TGF-β1, and IgE are involved in the pathogenesis of wheezing in these children. Airway inflammation is also observed in these children with wheezing, but it is not associated with the number of wheezing episodes, presence or absence of high-risk factors for asthma, or results of pathogen detection.
  • Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. [Journal Article]
    Pediatr Pulmonol 2019Gupta A, Pouliquen I, … Yancey SW
  • CONCLUSIONS: In children 6 to 11 years-of-age with severe eosinophilic asthma, mepolizumab SC 40 or 100 mg provided bodyweight-adjusted drug exposure within twofold of target adult exposure as well as marked reductions to blood eosinophil counts similar to adults, and although not designed to evaluate efficacy outcomes, demonstrated a positive clinical profile.
  • Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. [Journal Article]
    Int J Chron Obstruct Pulmon Dis 2019; 14:1779-1787Mkorombindo T, Dransfield MT
  • Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary disease continue to suffer acute exacerbations. It is also clear that a subset of this population has elevated blood eosinophils. In addition to clearly responding better to inhaled corticosteroids, it is also possible that this subgroup may benefit from biologic treatments targeting eosinophilic inflammation…
  • Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion. [Case Reports]
    Respir Med Case Rep 2019; 28:100927Tello K, Hoffmann A, … Koczulla AR
  • We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a s…
  • Severe Eosinophilic Asthma. [Review]
    J Clin Med 2019; 8(9)Bakakos A, Loukides S, Bakakos P
  • Asthma is a heterogeneous disease with varying severity. Severe asthma is a subject of constant research because it greatly affects patients' quality of life, and patients with severe asthma experience symptoms, exacerbations, and medication side effects. Eosinophils, although at first considered insignificant, were later specifically associated with features of the ongoing inflammatory process i…
  • Impact of adenotonsillectomy on the evolution of inflammatory markers. [Journal Article]
    Clin Otolaryngol 2019Marcano-Acuña ME, Carrasco-Llatas M, … Codoñer-Franch P
  • Lymphoid organs of Waldeyer's ring, mainly the palatal and pharyngeal (adenoid) tonsils, are the first immunocompetent tissues contacting exogenous microorganisms because of their strategic location at the entry of the respiratory and digestive systems.1 Tonsils are secondary lymphoid organs included in the mucosa-associated lymphoid tissue. They are organized in a manner closely related to their…
New Search Next